(Q44937084)

English

Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

8

object named as

Sergio Giralt

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Gregory Daniel Ayers

3

object named as

Gregory Ayers

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Richard E Champlin

5

object named as

Richard Champlin

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

4

object named as

Michele Donato

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Raymond Alexanian

7

object named as

Raymond Alexanian

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

author name string

Ana Aleman

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Donna Weber

6

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Athanasios Anagnostopoulos

1

0 references

language of work or name

0 references

publication date

1 June 2004

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

100

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

2607-2612

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20294

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy and innovative approaches to treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20294

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20294

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20294

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20294

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20294

7 January 2021

based on heuristic

inferred from DOI database lookup

Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20294

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20294

7 January 2021

based on heuristic

inferred from DOI database lookup

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20294

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20294

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20294

7 January 2021

based on heuristic

inferred from DOI database lookup

Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20294

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20294

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.20294

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44937084&oldid=2058770137"